Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
Journal of Integrative Medicine · 2026-05 · 24 (3) · 365-375
DOI: 10.1016/j.joim.2026.03.003 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Integrative Medicine, 2026-05. Verfasst von Fei-Peng Xu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Liver Diseases, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Clin…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
BACKGROUND: The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing. Yinchenhao Decoction (YCHD) has been well studied for its uses in treating NAFLD. Moreover, the metabolism of bile acids (BAs) and eicosanoids have influence on NAFLD. YCHD is a classic prescription for damp-heat syndrome, and can regulate BA metabolism and alleviate inflammation in NAFLD. OBJECTIVE: This study evaluated the effects of YCHD on NAFLD and explored the effect of YCHD on eicosanoids and BAs. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This randomized, double-blind, placebo-controlled trial enrolled 130 NAFLD participants. The participants were randomly assigned to YCHD group or placebo group in a 1:1 ratio, receiving YCHD granules or the placebo for 24 weeks. OUTCOME MEASURES: Primary outcome was absolute change in liver magnetic resonance imaging proton density fat fraction (MRI-PDFF) from the baseline to week 24. Secondary outcomes included absolute changes in controlled attenuation parameter (CAP), metabolic parameters, and liver injury and function parameters. RESULTS: After 24 weeks of treatment, MRI-PDFF (average), CAP, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and body mass index (BMI) decreased significantly in the YCHD group compared to placebo group (all P 0.05); however it did regulate taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA), deoxycholic acid (DCA), glycolithocholic acid (GLCA), and the ratio of GDCA to total BAs, compared to the placebo at week 24 (P < 0.05). CONCLUSION: YCHD can reduce the MRI-PDFF, CAP, ALT, AST, ALP and BMI without significant adverse events. YCHD can also regulate the metabolism of TDCA, GDCA and DCA, and the ratio of GDCA to total BAs. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000034868. Please cite this article as: Xu FP, Yang C, Yu SH, Cai H, Hui MY, Fang LL, Chen GF, Jiang SL, Qi SL, Wu SJ, Liu SJ, Yuan J, Xu G, Liu W, Liu P, Zhang H. Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. J Integr Med. 2026; 24(3):365-375.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Liver Diseases, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital, Shanghai University of Traditional C…
- Department of Hepatology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, Fujian Province, China.
- Department of Pharmacy, the State Administration of Traditional Chinese Medicine (SATCM) Third Grade Laboratory of Traditional Chinese Medicine Preparations, Shuguang Hospital, Shanghai University of Traditional Chinese…
- The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- Department of Radiology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- School of Public Health, Shanghai Jiao Tong University, Shanghai 200025, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Xu, F. P., Yang, C., Yu, S. H., Cai, H., Hui, M. Y., Fang, L. L., Chen, G. F., Jiang, S. L., Qi, S. L., Wu, S. J., Liu, S. J., Yuan, J., Xu, G., Liu, W., Liu, P., & Zhang, H. (2026). Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Journal of Integrative Medicine, 24(3), 365-375. https://doi.org/10.1016/j.joim.2026.03.003
Vancouver
Xu FP, Yang C, Yu SH, Cai H, Hui MY, Fang LL, et al. Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Journal of Integrative Medicine. 2026;24(3):365-375. doi:10.1016/j.joim.2026.03.003
BibTeX
@article{Xu2026,
author = {Xu, Fei-Peng and Yang, Chen and Yu, Shang-Hai and Cai, Hong and Hui, Meng-Yu and Fang, Ling-Ling and Chen, Gao-Feng and Jiang, Shi-Li and Qi, Shen-Lan and Wu, Si-Jia and Liu, Si-Jie and Yuan, Jie and Xu, Gang and Liu, Wei and Liu, Ping and Zhang, Hua},
title = {Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial},
journal = {Journal of Integrative Medicine},
year = {2026},
volume = {24},
number = {3},
pages = {365--375},
doi = {10.1016/j.joim.2026.03.003}
}
EUVIMED